These findings underscore the limitations of PD-L1 expression as a solitary predictive biomarker and stress the importance of incorporating additional testing methods, such as tumour mutational burden, immune gene profiling, and liquid biopsy technologies into clinical practice. The gene discussed is CD274; the disease is neoplasm.